Minocycline with aspirin: An approach to attenuate diabetic nephropathy in rats

Renal Failure

Volumn 33, Issue 1, 2011, Pages 72-78

  Kumar Bhatt, Lokesh ^a   Addepalli, Veeranjaneyulu ^a  

^a Shri Vile Parle Kelavani Mandal's Narsee Monjee Institute of Management Studies   (India)

Author keywords

Diabetic nephropathy; Extracellular matrix; Matrix metalloproteinase 2; Matrix metalloproteinase 9

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE; GELATINASE A; GELATINASE B; MINOCYCLINE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; KIDNEY FIBROSIS; KIDNEY FUNCTION TEST; KIDNEY HYPERTROPHY; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; RENAL ARTERY; UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URINE VOLUME; ZYMOGRAPHY;

ANIMALS; ASPIRIN; CYCLOOXYGENASE INHIBITORS; DIABETIC NEPHROPATHIES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MINOCYCLINE; RATS; RATS, WISTAR;

EID: 78651291885     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.528117     Document Type: Article

References (34)

1. Atkins RC. The epidemiology of chronic kidney disease. Kid ney Int. 2005;67:S14-S18.
2. Leehey DJ. Hemodialysis in the diabetic patient with end-stage renal disease. Ren Fail. 1994;16(5):547-553.
3. Hostetter TH. Hypertrophy and hyperfunction of the diabetic kidney. J Clin Invest. 2001;107:161-162.
4. Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19:433-442.
5. Williams ME, Tuttle KR. The next generation of diabetic nephropathy therapies: An update. Adv Chronic Kidney Dis. 2005;12:212-222.
6. Mauer SM. Structural-functional correlations of diabetic nephropathy. Kidney Int. 1994;45(2):612-622.
7. McLennan SV, Kelly DJ, Cox AJ, et al. Decreased matrix degradation in diabetic nephropathy: Effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Dia-betologia. 2002;45(2):268-275.
8. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix met-alloproteinases: Structures, evolution, and diversification. FASEB J. 1998;12:1075-1095.
9. Yurchenko PD, Schittney JC. Molecular architecture of the basement membrane. FASEB J. 1990;4:1577-1590.
10. Petitclerc E, Boutaud A, Prestayko A, et al. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem. 2000;275(11): 8051-8061.
11. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
12. Matresian LM. The matrix-degrading metalloproteinases. Bio-assays. 1992;14:455-463.
13. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007;6(6): 480-498.
14. Ahuja TS. Doxycycline decreases proteinuria in glomerulone-phritis. Am J Kidney Dis. 2003;42:376-380.
15. Bhatt LK, Veeranjaneyulu A. Minocycline with aspirin: A therapeutic approach in the treatment of diabetic neuropathy. Neurol Sci. 2010 [Epub ahead of print] PMID: 20213226.
16. Bhatt LK, Veeranjaneyulu A. Attenuation of diabetic retinopa-thy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats. Am J Transl Res. 2010;2(2):181-189.
17. O'Connor AS, Schelling JR. Diabetes and the kidney. Am J Kidney Dis. 2005;46:766-773.
18. Kexin XU, Shukun HOU, Zhijun DU. Prognostic value of matrix metalloproteinase-2 and tissue inhibitor of metall-oproteinase-2 in bladder carcinoma. Chinese Med J. 2002; 115(5):743-745.
19. Suzuki D. Metalloproteinases in the pathogenesis of diabetic nephropathy. Nephron. 1998;80(2):125-133.
20. Vlassara H, Striker LJ, Teichberg S. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA. 1994;91:11704-11708.
21. Senatorski G, Paczek L, Sulowicz W. Urine activity of cathep-sin B, collagenase and urine excretion of TGF-beta 1 and fibronectin in membranous glomerulonephritis. Res Exp Med (Berl). 1998;198:199-206.
22. Zaoui P, Cantin JF, Alimardani-Bessette M. Role of metallopro-teases and inhibitors in the occurrence and progression of diabetic renal lesions. Diabetes Metab. 2000;26(suppl. 4):25-29.
23. Fogo AB. Current concepts in glomerulosclerosis. Am J Kidney Dis. 1999;34(5):LIV-LVI.
24. Kurogi Y. Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. Med Res Rev. 2003;23:15-31.
25. Ziyadeh FN. Renal tubular basement membrane and collagen type IV in diabetes mellitus. Kidney Int. 1993;43: 114-120.
26. Brenner BM, Anderson S. The interrelationships among filtration surface area, blood pressure, and chronic renal disease. J Cardiovasc Pharmacol. 1992;19(suppl. 6):S1-S7.
27. McMillan JI, Riordan JW, Couser WG. Characterization of aglomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J Clin Invest. 1996;97: 1094-1101.
28. Ebihara I, Nakamura T, Shimada N, Koide H. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis. 1998;32:544-550.
29. Steinmann-Niggli K, Ziswiler R, Kung M, Marti HP. Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J Am Soc Nephrol. 1998;9:397-407.
30. Sugimoto K, Tsuruoko S, Fujimura A. Effect of enalapril on diabetic nephropathy in OLETF rats: The role of an anti-oxidative action in its protective properties. Clin Exp Pharmacol Physiol. 2001;28:829-830.
31. Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer. Clin Cancer Res. 2003;9(2):551-554.
32. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130:963-974.
33. Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev. 2003; 23:117-145.
34. Kaito K, Urayama H, Watanabe G. Doxycycline treatment in a model of early abdominal aortic aneurysm. Surg Today. 2003;33:426-433.